Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, announced new data recently presented on the clinical utility of Signatera, its personalized and tumor-informed molecular residual disease (MRD) test, at the American Society of Clinical Oncology’s 2022 Gastrointestinal Cancers Symposium (ASCO GI). The oral presentation included an updated analysis from the landmark CIRCULATE-Japan trial analyzing a cohort of colorectal cancer (CRC) patients.
+40 726 113 005
Str. Turturelelor nr. 62, Decebal Tower, et 2, sector 3, Bucuresti, 030882
